Chimeric Cell Therapy Transfers Healthy Donor Mitochondria in Duchenne Muscular Dystrophy

Area of Science:

• Cell Biology
• Regenerative Medicine
• Mitochondrial Biology

Background:

• Duchenne muscular dystrophy (DMD) is a severe X-linked genetic disorder.
• DMD is characterized by dystrophin gene mutations and mitochondrial dysfunction.
• This leads to progressive muscle weakness and premature death.

Purpose of the Study:

• To explore mitochondrial transfer and fusion within Dystrophin Expressing Chimeric (DEC) cells.
• To establish the feasibility of creating functional chimeric mitochondria for therapeutic applications.
• To support the development of DT-DEC01 therapy for DMD.

Main Methods:

• PEG-mediated fusion of myoblasts from normal and DMD-affected donors.
• Mitochondrial staining using MitoTracker Deep Red and MitoTracker Green dyes.
• Assessment of mitochondrial fusion and transfer via Flow cytometry (FACS) and confocal microscopy.

Main Results:

• Confirmed the feasibility of myoblast and mitochondrial fusion and transfer.
• Demonstrated the creation of chimeric mitochondria through the colocalization of mitochondrial dyes.
• Showcased the successful transfer of healthy donor mitochondria into DEC cells.

Conclusions:

• DT-DEC01 therapy has the potential to restore mitochondrial function in DMD patients.
• These findings highlight a novel therapeutic strategy for diseases involving mitochondrial dysfunction.
• DEC cells offer a promising platform for regenerative medicine in DMD.